Corrigendum

Fereshteh Alsahebfosoul, Ilnaz Rahimmanesh, Mansour Shajarian*, Masoud Etemadifar*, Nahid Sedaghat, Zahra Hejazi and Shamsi Naderi

Corrigendum to: Interleukin-33 plasma levels in patients with relapsing-remitting multiple sclerosis

https://doi.org/10.1515/bmc-2017-0030


On page 57, right column, end of the first paragraph, the expression “p > 0.001” should read “p < 0.001”. On page 58, left column, lines 19–22, the sentence “Although clinical studies have shown that administration of IL-33 causes development of inflammation in the EAE model (54), other investigations have declared that IL-33 is not a necessary element for EAE pathogenesis (55).” should read “Although clinical studies have shown that administration of IL-33 causes inhibition of inflammation in the EAE model (54), other investigations have declared that IL-33 is not a necessary element for EAE pathogenesis (55).” The authors apologize for the errors.

*Corresponding authors: Mansour Shajarian, Isfahan Research Center of Multiple Sclerosis, Isfahan, Iran; and Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran, e-mail: mansour.shajarian@gmail.com; and Masoud Etemadifar, Isfahan Research Center of Multiple Sclerosis, Isfahan, Iran; and Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran, e-mail: etemadifar@med.mui.ac.ir

Fereshteh Alsahebfosoul and Nahid Sedaghat: Isfahan Research Center of Multiple Sclerosis, Isfahan, Iran; and Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Ilnaz Rahimmanesh, Zahra Hejazi and Shamsi Naderi: Isfahan Research Center of Multiple Sclerosis, Isfahan, Iran; and Departments of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran